Erasca, Inc. Board of Directors

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Dr. Jonathan E. Lim M.D.

Dr. Jonathan E. Lim M.D.

Co-Founder, Chairman & CEO

Dr. Michael D. Varney Ph.D.

Dr. Michael D. Varney Ph.D.

Chairman of Research & Development, Scientific Advisory Board Member and Director

Mr. Brian L. Baker CPA, M.S.

Mr. Brian L. Baker CPA, M.S.

Senior Vice President of Finance

Dr. Nik Chetwyn Ph.D.

Dr. Nik Chetwyn Ph.D.

Chief Operating Officer

Dr. David M. Chacko M.D.

Dr. David M. Chacko M.D.

CFO & Chief Business Officer

Mr. Ebun S. Garner Esq., J.D.

Mr. Ebun S. Garner Esq., J.D.

General Counsel & Corporate Secretary

Dr. Robert Shoemaker Ph.D.

Dr. Robert Shoemaker Ph.D.

Senior Vice President of Research

Ms. Chandra D. Lovejoy M.S.

Ms. Chandra D. Lovejoy M.S.

Chief Regulatory Affairs Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.